Nasdaq biotechnology stocks reached a record high following an update on Moderna's experimental melanoma vaccine. The late-stage trial results were cited as a key driver of the sector's performance. Further details about the trial or its implications were not immediately available.
Moderna melanoma vaccine success lifts Nasdaq biotechs to record
A late-stage trial update on Moderna's experimental melanoma vaccine contributed to a milestone for Nasdaq biotech stocks.
PA
Priya Anand · Equities & Earnings Desk · 19 Aug 2026 · 15:09 · 1 min read
This article was produced with AI assistance and edited by a Finance Review Daily journalist.
ADVERTISEMENT
PA
Written by
Priya Anand
Equities & Earnings Desk
Priya covers listed equities and corporate earnings, reading quarterly results and guidance for what they signal about sector health and forward valuations.
More from Priya Anand →